Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Unknown 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Endocrine 4NET 2

Conditions

Neuroendocrine Tumors 15Paraganglioma 4Meningioma 4Carcinoma, Neuroendocrine 4Pheochromocytoma 3Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Medullary 2Carcinoid Tumor 2Somatostatinoma 1Serotonin Syndrome 1Prostatic Neoplasms 1Pituitary Neoplasms 1Parathyroid Neoplasms 1Neuroblastoma 1Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Hypertension 1Disease Progression 1Carcinoma, Merkel Cell 1Carcinoid Heart Disease 1Breast Neoplasms 1Advanced Lung Neuroendocrine Tumor 1Adenoma, Islet Cell 1

Interventions

Everolimus 9Cisplatin 8Temozolomide 6Nivolumab 5Etoposide 5Carboplatin 5Bevacizumab 5lutetium Lu 177 dotatate 4Capecitabine 4pembrolizumab 3Irinotecan 3sintilimab 2dostarlimab 2cabozantinib 2azaspirane 2avelumab 2atezolizumab 2Paclitaxel 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Ipilimumab 2Immunoglobulin G 2IFL protocol 2Fluorouracil 2Fluorodeoxyglucose F18 2Disulfides 2zimberelimab 1surufatinib 1selinexor 1pertuzumab 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Neuroendocrine × lutetium Lu 177 dotatate × Clear all
NCT01876771 2025-08-08

A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours

AHS Cancer Control Alberta

Phase 2 Recruiting
500 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT02236910 2024-10-15

Lu-DOTA-TATE

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 2 Unknown
66 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT02754297 2024-08-21

P-PRRT

CHU de Quebec-Universite Laval

Phase 2 Active not recruiting
275 enrolled
EndocrineNET

Carcinoid Tumor, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT04525638 2022-08-02

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

Fundación de investigación HM

Phase 2 Unknown
30 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡